Role of T Helper 17 and Regulatory T Cells in Delayed Graft Function
Can T Helper 17 and Regulatory T Cells Explain the Pathophysiology of Delayed Graft Function in Renal Transplant Recipients?
Sponsor: Astellas Pharma Canada, Inc.
Listed as NCT01232816, this observational or N/A phase trial focuses on Delayed Graft Function and remains ongoing. Sponsored by Astellas Pharma Canada, Inc., it has been updated 12 times since 2010, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
▶ Show 7 earlier versions
-
Jan 2020 — Nov 2020 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Oct 2019 — Jan 2020 [monthly]
Active Not Recruiting
-
Jun 2018 — Oct 2019 [monthly]
Active Not Recruiting
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting
-
Apr 2018 — May 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Active Not Recruiting NA
First recorded
Jul 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma Canada, Inc.
- McGill University Health Centre/Research Institute of the McGill University Health Centre
For direct contact, visit the study record on ClinicalTrials.gov .